efficacy of neoadjuvant androgen deprivation therapy fof high risk prostate cancer

efficacy of neoadjuvant androgen deprivation therapy fof high risk prostate cancer - efficacy of neoadjuvant androgen deprivation therapy fof high risk prostate cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028874

Enrollment

100

Registered

2017-09-10

Start date

2017-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

Degarelix and estramustine would be preoperatively administrated for 3 months. LH-RH agonist and estramustine would be preoperatively administrated for 3 months.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Localized prostate cancer evaluated as a high risk,PS; 0-1 Bone marrow suppression was not observed. Liver and renal function was within normal range.

Exclusion criteria

Exclusion criteria: The patients for whom Dutasteride or another androgen deprivation therapy was administrated.

Design outcomes

Primary

Measure	Time frame
Biochemical recurrence after radical prostatectomy	—

Countries

Japan

Contacts

Public ContactMasao Kataoka

Fukushima Medical University School of Medicine, Dept..of urology

masaoka@fmu.ac.jp0245471316

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026